Molecular Advances in Drug Resistance and Novel Therapies for Cancer
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Biological Factors".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 47
Special Issue Editors
Interests: biology of cancer; cell signalling; photobiology; cutaneous cells; melanoma; RIPK4
Interests: skin; biology of melanoma; melanogenesis; photobiology; dermatopathology; cutaneous cells; mitochondria; oxidative stress; melatonin and its metabolites
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer drug discovery has immensely advanced since its earliest steps. Nevertheless, rare occurrences of anti-cancer-drug-resistant cancers show a poor prognosis via recurrence or metastasis, and these consequences can be associated with patient death. Various studies have shown that recurrent or metastatic cancer is refractory to most medical treatments. These refractory cancers are usually slow; however, following anaplasia of the injury, they are altered into poorly differentiated and undifferentiated cancer, described by a sharp expansion involving a poor prognosis. The stemness and aggressiveness of refractory cancer has not yet been revealed. Studies looking at the outcomes from the advancement of anti-cancer drugs have described that pre-operative chemotherapy can extend survival rates after surgery. Nonetheless, no selective therapeutic options have been accepted as the basal adjuvant or neoadjuvant background for drug-resistant cancer, and a substantial number of anti-cancer-drug-resistant cancer patients have died; therefore, unmet medical needs have consistently increased. Refractory cancer due to drug resistance, which mediates metastasis and recurrence, is a decisive part of unmet medical needs. Anti-cancer drug resistance remains a fundamental challenge in the treatment of patients with refractory cancer. For these reasons, anti-cancer drug resistance in refractory cancer represents a primary challenge in cancer therapy.
The goal of the enclosed Special Issue is to collect the latest findings on a broad range of research including basic research in vitro, preclinical models involving substances potentially used as breakthrough clinical solutions for drug-resistant tumours, and newly introduced compounds targeting cancer therapy. We welcome original experimental research, review articles, and commentary articles describing the above aspects of this devastating disease.
We look forward to receiving your contributions.
Dr. Agnieszka Wolnicka-Glubisz
Dr. Konrad Kleszczyński
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cell signalling
- cancer treatment
- cancer metastasis
- target validation
- cancer and new molecules
- cancer and cellular organelles
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
